Evidence map›Paper›PMID 41473281›Full record

ArticlebioRxiv : the preprint server for biology2025

Mechanisms of tumor persistence in metastatic melanoma following successful immunotherapy.

Yingxiao Shi, Zoltan Maliga, Tuulia Vallius, Shishir M Pant, Roxanne Pelletier, Brigette Kobs, Solanky Priyanka, Yiwen He, Eliezer Van Allen, Sandro Santagata and 5 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yingxiao ShiLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.ORCID 0000-0003-2783-9642
Zoltan MaligaLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.ORCID 0000-0003-4209-7253
Tuulia ValliusLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.ORCID 0000-0002-3006-4887
Shishir M PantLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.ORCID 0000-0002-2686-7898
Roxanne PelletierLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.ORCID 0000-0002-1957-5483
Brigette KobsLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.ORCID 0000-0003-3417-7472
Solanky PriyankaDivision of Population Sciences, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215.ORCID 0009-0009-7374-467X
Yiwen HeDivision of Population Sciences, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215.ORCID 0000-0002-3841-4431
Eliezer Van AllenDivision of Population Sciences, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215.ORCID 0000-0002-0201-4444
Sandro SantagataLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.ORCID 0000-0002-7528-9668
Patrick OttDepartment of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215.ORCID 0000-0002-4253-943X
Christine G LianLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.ORCID 0000-0003-4626-1612
Elizabeth I BuchbinderDepartment of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215.ORCID 0000-0002-7979-8953
David LiuLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.ORCID 0000-0003-0346-5033
Peter K SorgerLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.ORCID 0000-0002-3364-1838

Funding

VectorP30CA006516 · NCI · DANA-FARBER CANCER INSTITUTE · PI Irene M. Ghobrial · 1985 to 2026
$330.6M
Dissecting Therapeutic Resistance and Progression in Metastatic Melanoma Through Clinical Computational OncologyK08CA234458 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI LIU, DAVID · 2018 to 2022
$1.2M
High dimensional digital pathology to investigate the tumor micro environment and its impact on response to therapyR50CA252138 · NCI · HARVARD MEDICAL SCHOOL · PI MALIGA, ZOLTAN · 2020 to 2024
$1.0M
NCI NIH HHS K08 CA234458NCI NIH HHS P30 CA006516NCI NIH HHS R50 CA252138
6 · The paper itself

Abstract

Persistent stable lesions represent a common but ambiguous outcome in melanoma patients receiving immune checkpoint inhibitors (ICIs). However, these lesions are infrequently removed and poorly characterized. Here, we perform in-depth multi-omics spatial profiling on persistent stable lesions from six ICI-treated patients. In one, the proportion of viable and proliferating tumor cells was similar to that of site-matched tumors from patients progressing during ICI. Extensive infiltration with cytotoxic T cells and a high level of programmed cell death were also observed. Some quiescent cancer cells were present, but this was not the dominant tumor state. A second stable lesion, while pathologically negative, also contained proliferative tumor nests with proximate immune cells. These findings provide evidence in patients for extended tumor mass dormancy in which cell death balances ongoing proliferation and further demonstrate that persistent stable lesions can be reservoirs of viable tumor cells with implications for clinical monitoring and management.

Identifiers

PMID41473281
PMCPMC12746126

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.